Total | 57 | 23 | 24 | |
Male | 25 (44) | 7 (30) | 18 (75) | 0.006 |
Sputum | | | | |
Non-Pseudomonas | 10 | 1 | 2 | 0.54 |
Intermittent Pseudomonas | 10 | 2 | 4 | |
Chronic Pseudomonas | 36 | 19 | 17 | |
Burkholderia cepacia | 1 | 1 | 1 | |
Cystic fibrosis related diabetes | 37 (65) | 15 (65) | 19 (79) | 0.43 |
Location of exacerbation treatment | | | | 0.73 |
Hospital | 21 | 6 | 11 | |
Home | 11 | 11 | 8 | |
Both | 6 | 6 | 5 | |
Viral symptoms | 32 (56) | 13 (57) | 9 (38) | 0.31 |
Length of treatment days | 14 (6–100) | 14 (9–32) | 14.5 (1–31) | 0.67 |
Baseline CRP mg·L−1 | 26.5 (0–176) | 24.0 (0–263) | 21.5 (0–154) | 0.43 |
Post CRP mg·L−1 | 10.4 (0–144) | 7.1 (0–35) | 6.5 (10–53) | 0.52 |
FEV1 best 6 month prior % pred | 51 (16–103) | 52 (20–91) | 45.5 (15–126) | 0.47 |
FEV1 best 6 month post % pred | 49 (11–108) | 48 (24–89) | 40 (15–118) | 0.51 |
Change in FEV1 % pred | −3 (−32–9) | −4 (−13–14) | -3 (−11–5) | 0.54 |
Time to next exacerbation days | 44 (0–725) | 46.5 (0–271) | 47 (7–211) | 0.70 |
Exacerbations 1 year prior | 4 (0–14) | 3 (0–8) | 3 (1–6) | 0.95 |
Exacerbations 1 year post | 4 (0–18) | 4 (0–10) | 3 (0–8) | 0.25 |